Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 11:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 8,540 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gastro-intestinal Clear all
Terminated Phase 2 Interventional

VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease

NCT05688852
View directory record Official record
Conditions
Crohn Disease
Interventions
VTX958, VTX958 Placebo
Drug
Lead sponsor
Ventyx Biosciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
26
States / cities
Garden Grove, California • Lancaster, California • Kissimmee, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jun 10, 2026, 11:29 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome

NCT00081458
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Placebo, Teduglutide 0.05 mg/kg/d, Teduglutide 0.1 mg/kg/d
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
14
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Jun 10, 2026, 11:29 AM EDT
Terminated Not applicable Interventional Results available

Gastrointestinal Tract Recovery in Patients Undergoing Open Ventral Hernia Repair

NCT02379858
View directory record Official record
Conditions
Ventral Hernia
Interventions
Alvimopan, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Jun 10, 2026, 11:29 AM EDT
Completed Phase 3 Interventional

Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus

NCT00388258
View directory record Official record
Conditions
Ileus
Interventions
Alvimopan
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Exton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Jun 10, 2026, 11:29 AM EDT
Completed Not applicable Interventional

Migration Rates of Sutured vs Non-sutured Esophageal Stent Placement

NCT05082948
View directory record Official record
Conditions
Dysphagia, Esophageal, Esophageal Cancer
Interventions
Suture fixation of stent, Non suture
Other
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 99 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Jun 10, 2026, 11:29 AM EDT
Withdrawn Not applicable Interventional

Mobility and Activity Training (MAT) to Optimize Outcomes for Older Adult Abdominal Surgery Patients

NCT02007876
View directory record Official record
Conditions
Gastrointestinal Malignancy
Interventions
Mobility and Activity Training
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
60 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Jun 10, 2026, 11:29 AM EDT
Completed Not applicable Interventional Results available

Randomized Controlled Trial of a Patient Activation Tool in Pediatric Appendicitis (Antibiotics Alone vs. Appendectomy)

NCT02110485
View directory record Official record
Conditions
Appendicitis, Children
Interventions
Patient Activation Tool
Other
Lead sponsor
Peter Minneci
Other
Eligibility
7 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Jun 10, 2026, 11:29 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

NCT04602117
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2 Low, SYD-985, SYD985, Vic-trastuzumab Duocarmazine, Metastatic Cancer, Metastatic Breast Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic, HER2 Low Breast Cancer, GastroEsophageal Cancer, Gastroesophageal Adenocarcinoma, Endometrium Tumor, Ovarian Cancer, Ovarian Carcinoma, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2 Low HR Positive, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Bladder Cancer
Interventions
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jun 10, 2026, 11:29 AM EDT
Recruiting No phase listed Observational

CTNNA1 Familial Expansion Study

NCT05126290
View directory record Official record
Conditions
Cancer Gene Mutation, Gastric Cancer, Breast Cancer
Interventions
Collection of personal and family history from CAFÉ Study participants
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jun 10, 2026, 11:29 AM EDT
Completed Phase 1 Interventional

RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease

NCT02838797
View directory record Official record
Conditions
Parkinson's Disease, Gastroparesis, Constipation
Interventions
RQ-00000010, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Henrico, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Jun 10, 2026, 11:29 AM EDT
Terminated Phase 2 Interventional Results available

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

NCT04383210
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer, Head and Neck Cancer, Breast Cancer, Kidney Cancer, Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Sarcoma, Gallbladder Cancer, Bile Duct Cancer, Esophageal Cancer, Uterine Cancer, Cholangiocarcinoma, Prostate Cancer
Interventions
Seribantumab
Drug
Lead sponsor
Elevation Oncology
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Jun 10, 2026, 11:29 AM EDT
Completed Not applicable Interventional

Response of the Gut Microbiome and Circulating Metabolome to Diet in Children: Ancillary Study to KIDFIT (NCT03405246)

NCT03612479
View directory record Official record
Conditions
Gastrointestinal Microbiome, Metabolome, Pediatric Obesity, Dietary Approaches to Stop Hypertension
Interventions
KIDFIT Healthy, KIDFIT Safe
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
3 Years to 5 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Jun 10, 2026, 11:29 AM EDT
Completed Phase 4 Interventional

Esomeprazole for Treatment of GERD in Pediatric Patients

NCT00228527
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, Non-erosive Esophagitis
Interventions
Esomeprazole (Nexium)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
24
States / cities
Mobile, Alabama • Phoenix, Arizona • Wilmington, Delaware + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Jun 10, 2026, 11:29 AM EDT
Recruiting No phase listed Observational

Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study

NCT05994482
View directory record Official record
Conditions
Colorectal Cancer
Interventions
adenoma vs no adenoma, colonoscopy vs no colonoscopy, survey and expert panel
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
75 Years and older
Enrollment
130,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
San Diego, California • West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jun 10, 2026, 11:29 AM EDT
Completed No phase listed Observational

Patient-Reported Outcomes in Long-Term Survivors of Colon and Rectal Cancers

NCT00410579
View directory record Official record
Conditions
Colorectal Cancer, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Pain, Psychosocial Effects of Cancer and Its Treatment
Interventions
Telephone interview
Other
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
Not listed
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
200
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 132 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2010 · Synced Jun 10, 2026, 11:29 AM EDT
Recruiting Not applicable Interventional

Community Partnership for Telehealth Solutions to Convey Information and Enhance Care

NCT06542835
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Video text message, In-clinic CRC screening promotion, Mailed FIT, Social needs navigation, Reminders
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
45 Years to 64 Years
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jun 10, 2026, 11:29 AM EDT
Not listed Phase 3 Interventional

Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.

NCT00337389
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
Interventions
5- Fluorouracil (5-FU), bevacizumab (Avastin), Leucovorin, CoFactor (ANX-510)
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
46
States / cities
Florence, Alabama • Anaheim, California • Apple Valley, California + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2007 · Synced Jun 10, 2026, 11:29 AM EDT
Completed Phase 2 Interventional Results available

Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer

NCT01262560
View directory record Official record
Conditions
Dysphagia, Lung Cancer, Pain, Esophagitis
Interventions
Manuka honey in liquid form, Manuka honey in lozenge form, Standard supportive care
Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
59
States / cities
Mobile, Alabama • San Francisco, California • Stanford, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Jun 10, 2026, 11:29 AM EDT
Completed Phase 1 Interventional

Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer

NCT02110082
View directory record Official record
Conditions
Colorectal Cancer, Head and Neck Cancer
Interventions
Urelumab, Cetuximab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Stanford, California • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Jun 10, 2026, 11:29 AM EDT
Active, not recruiting Phase 4 Interventional Results available

Use of the LEVA® Pelvic Health System for Fecal Incontinence

NCT06152224
View directory record Official record
Conditions
Fecal Incontinence
Interventions
The Leva Pelvic Health System
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Jun 10, 2026, 11:29 AM EDT
Terminated No phase listed Observational

Small Bowel Transit Time in Clostridium Difficile Colitis

NCT01309750
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
Small Bowel Transit Study
Radiation
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Jun 10, 2026, 11:29 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Sensorimotor Dysfunction in Achalasia

NCT02434991
View directory record Official record
Conditions
Achalasia
Interventions
Barostat
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Jun 10, 2026, 11:29 AM EDT
Recruiting Phase 1 Interventional

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT04222413
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer, Malignant Peripheral Nerve Sheath Tumor, Colorectal Neoplasms
Interventions
Metarrestin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Fairway, Kansas • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 10, 2026, 11:29 AM EDT
Completed Phase 2 Interventional

Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer

NCT00215982
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, Oxaliplatin, Irinotecan
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Jun 10, 2026, 11:29 AM EDT